Exchange: NASDAQ·Updated 07:30 PM EST
OCUL logo

OCUL Ocular Therapeutix Inc

$5.60
$0.29
(4.95%)
Today
Closed $5.57
$0.03
(0.54%)
After Hours
Reported EarningsNov 9
Mkt Cap$1.23B
Vol2.9M

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
47

Neutral Sentiment

How do you feel about OCUL?

IchthysTrades
$OCUL Don't let the algorithmic bot headlines distract you from the biggest breaking development in this morning's update: 1. SOL-X is officially moving to 48-WEEK dosing (once a year). This was not on the market's radar. Management upgraded the protocol from 6 months to annual maintenance based on the extended durability demonstrated in SOL-1. AXPAXLI is no longer being pitched just to match standard anti-VEGF intervals—it is positioning to become an annual maintenance monopoly. 2. Added Dr. Riad Sherif to the Board of Directors. Current CEO of Oculis with former senior leadership at Sanofi, Novartis, and Alcon. 3. IMO, The pipeline’s commercial ceiling and the takeover floor just moved higher. Know what you hold. 🎯💎
1
13
Thundr1
$OCUL As an OG holder, I know this share price is painful. But the plan Dugel outlined is still moving forward: FDA alignment on the wet AMD NDA, $530.6M in cash with runway into 2028, and HELIOS-3 advancing in diabetic retinopathy. SOL-R timing has shifted, but the bigger opportunity remains. The stock is bleeding; the company isn’t bleeding out.
12
BirdWithBigBalls
$OCUL OCUL is significantly shorted, and the level of short interest is high enough to create meaningful short-squeeze potential.
1
13
ShortSuckieTuckie
$OCUL We've all been focused on wetAMD over the past 8 months. We shouldn't loose sight of the Helios study. This is a brilliantly designed study and I have to tip my hat to management for designing such a study and getting the FDA to agree to it with a SPA. It truly judges Axpaxli's ability to have a better outcome versus the standard of care today, which is to do nothing. If you were to use the data from Helios 1 and judge whether the results were statistically significant, the answer is yes. That is amazing IMO with such a small trial. Q1 2028 is turning out to be what could be a very transformational year for OCUL. They "should" have Axpaxli on the market for wetAMD, be revealing how Axpaxli performed against Eylea HD and revealing top line Helios 3 data. I keep going back to Dr Heier's excitement about bring Axpaxli to market for NPDR because there is nothing on the market that patients would accept.
13
SmokenTuna
$OCUL depressing..trying to keep my chin up but longs here have been destroyed over and over.
9
esu89
$OCUL have been waiting for the right time to make 2026 Roth contributions. Pulled the trigger today for wife and myself and bought 1,314 shares more for both of us at $6.55.
13
SmokenTuna
$OCUL everything in this country is either manipulated, laundered, deceitfully presented, and just stolen. Our stock market is a derivative of all the above combined.
12
JoeBio
$OCUL It's frustrating to see a company with positive Phase 3 superiority data trading at a valuation that seems disconnected from both the strength of the clinical results and the premiums being paid for much earlier-stage ophthalmology assets. To me, the market isn't disputing the SOL-1 data. The discount reflects uncertainty around OCUL's NDA approval, commercial execution, and adoption. Many programs promise. Few deliver superiority. AXPAXLI already has. My view, and where I've put alot of my money, is that we're not looking at a future competitor, we're looking at the potential future category leader.
1
8
ShortSuckieTuckie
$OCUL Note that they refer to Regulatory Agencies and not just the FDA when referring to SOL-R.
12
Appulen
$OCUL another inducement. The company has hired almost 100 new people this year alone. FDA approval is about 9 months away. They must be very bullish on those sales to invest in so many people.
8
DrKyle
$OCUL Having been around since the Dextenza years....I had always hoped that we would also license this technology for the greater good and help with the issue of chronic pain management and reduce the amount of people addicted to opioids, while at the same time making a handsome profit. I understand the value in keeping 100% control in the event you want a future buyout. To me a potential acquirer one day will not only be getting the value from our retina products but a hidden gem in the delivery system to potentially repackage an already existing med in their arsenal.
12
MaxKlim
$OCUL How did Iveric Bio (ISEE) behave before its buyout? 1. An artificial decline to lows ahead of the NDA filing • As Iveric Bio prepared to submit its New Drug Application (NDA) to the FDA • The share price was effectively "driven into the ground," falling to 52-week lows in the $9.00–$10.00 range. Retail investors panicked, while forums like Stocktwits and Reddit were flooded with claims that the company was a "sham" and that its management was incompetent. 2. Pravin Dugel’s defense and a strict "Quiet Period" • Much like the current situation with OCUL, Pravin Dugel and the Iveric Bio team entered a mandatory regulatory "quiet period." They were unable to comment on the manipulation of the stock price, which gave market makers free rein to push the shares lower on below-average trading volume.
12
IchthysTrades
$OCUL Let’s do the M&A math: J&J just dropped $3.4B on Ollin for an early-stage eye asset. If an unproven, pre-Phase 3 pipeline is worth over $3B, what is $OCUL actually worth? We already have proven Phase 3 superiority data, an active FDA SPA for Diabetic Retinopathy, and a fully de-risked Wet AMD NDA filing dropping next month. The ophthalmic arms race is here and we are the crown jewel. $OCUL
11
BirdWithBigBalls
$OCUL this is worse than the time i found out my gf was cheating on me with Jensen Huang
11
ShortSuckieTuckie
$OCUL The way I see it is you have the following risks that need to be resolved before OCUL achieves full valuation. 1. Safety Risk (hopefully gets answered when the NDA gets submitted and they mention that there were no new or unforeseen safety events). If there is no mention of safety, then that remains a overhang. 2. NDA acceptance on 1 trial. This will be addressed 60 days after submission. 3. Label .... will they or won't they get redosing based upon SOL-1? Requires approval in or around August 4. Market adoption... depends on payers and clinicians. They've been doing a lot of outreaches to both. The good news is that Medicare Part B with Medigap accounts for 35% of the Market which can be converted by Dr's without having to go thru the step process. The reality is, we don't see a "fair" price on this until approval when we know what the label says. This is primarily due to the issue of nobody ever getting a drug approved for wetAMD in the past with a Superiority trial...
11
MaxKlim
$OCUL An announcement regarding the submission of an NDA could come any day—as soon as the third-party company finishes compiling the safety data table for SOL R.
11
MaxKlim
$OCUL It appears that top managers will only be able to make purchases after an NDA has been signed; they currently possess non-public information regarding the bid.
7
fsu45
$OCUL I believe in what we (OCUL) has BUT good lord. This stock is enough to give anyone heartache!
10
Kynoch
$OCUL I was not expecting this to hit a 52wk low today. If they are pushing this down to load up then I'll add too. Seems like a discount when you think about what is coming.
8
DefiDynasty
$OCUL valuation still looks way too cheap given the pipeline here. Market hasn't caught up to the story yet. Patience pays with setups like this. Watching closely.
10

Advertisement|Remove ads.